Hot Features
Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
MINDBIO THERAPEUTICS BEGINS DOSING MB22001 IN PHASE 2 CLINICAL TRIAL IN WORLD FIRST TAKE-HOME MICRODOSING STUDY IN PATIENTS WITH DEPRESSION World-first take-home approvals...
MINDBIO THERAPEUTICS BREAKTHROUGH DISCOVERY IN MICRODOSING CLINICAL TRIAL REVEALS SIGNIFICANT POSITIVE EFFECTS ON QUALITY OF SLEEPNew Discovery: MindBio's LSD-Microdosing Treatment Improves...
MINDBIO THERAPEUTICS CEO DEMONSTRATES HOW 1 MILLION MICRODOSES OF LSD CAN POTENTIALLY BE USED TO TREAT DEPRESSION 1 Million Microdoses used to create proprietary microdosing...
ETHICS APPROVAL FOR LANDMARK WORLD FIRST PHASE 2 CLINICAL TRIAL OF TAKE-HOME LSD-MICRODOSING FOR MAJOR DEPRESSIVE DISORDEREthics approval received for take-home LSD-Microdosing clinical...
PHASE 2 CLINICAL TRIAL HAS RECEIVED ETHICS APPROVAL FOR WORLD FIRST TAKE-HOME LSD-MICRODOSING TRIALS IN CANCER PATIENTS EXPERIENCING EMOTIONAL DISTRESSEthics approval granted The clinical trial...
MindBio Therapeutics Corp (CSE: MBIO) Reveals Scientific Paper in World-First Take-Home, LSD-Microdosing Clinical Trial in 80 Healthy Participants MindBio clinical trial...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.005 | 25 | 0.02 | 0.025 | 0.02 | 342729 | 0.02006998 | CS |
| 4 | -0.005 | -16.6666666667 | 0.03 | 0.035 | 0.02 | 200299 | 0.02503913 | CS |
| 12 | -0.005 | -16.6666666667 | 0.03 | 0.035 | 0.02 | 83535 | 0.02564268 | CS |
| 26 | -0.025 | -50 | 0.05 | 0.06 | 0.02 | 61474 | 0.03057281 | CS |
| 52 | 0 | 0 | 0.025 | 0.085 | 0.015 | 56382 | 0.0388336 | CS |
| 156 | -0.535 | -95.5357142857 | 0.56 | 0.56 | 0.015 | 67034 | 0.05842093 | CS |
| 260 | -0.535 | -95.5357142857 | 0.56 | 0.56 | 0.015 | 67034 | 0.05842093 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Premium
